Andreas Herrmann

This inventor holds 7 USPTO granted patents and 1 published patent application and 5 EPO patents. Top assignees: Baliopharm Ag, Probiocon Gmbh, Baliopharma Ag. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andreas Herrmann. Retrieved from https://idiyas.com/inventor/andreas-herrmann-1xju67rx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 71.4

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 17(Granted Patents)

Location History:

Allschwil, CH (2015)
Pfeffingen, CH (2014 - 2024)

Company Filing History:

Universitãt Stuttgart

patents

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12048744 - RANKL-specific agent for treating metastatic disease (2024-07-30),

2. 11028178 - Method of treating nonalcoholic steatohepatitis by administering an antagonist human tumor necrosis factor receptor 1 (HUTNFR1) antibody (2021-06-08),

3. 10806786 - RANKL-specific agent for treating metastatic disease (2020-10-20),

4. 10689452 - Monovalent anti-huTNFR1 antibodies, encoding nucleic acids thereof and methods of treatment thereof (2020-06-23),

5. 10590202 - Recombinant bispecific antibody binding to CD20 and CD95 (2020-03-17),

6. 9133485 - Methods and materials for the reproducible generation of high producer cell lines for recombinant proteins (2015-09-15),

7. 8859739 - Anti-huTNFR1 antibody and methods of use thereof for treatment (2014-10-14),

Title: The Innovative Contributions of Andreas Herrmann

Introduction

Andreas Herrmann is a notable inventor based in Pfeffingen, Switzerland. He has made significant contributions to the field of medical research, particularly in the development of treatments for various diseases. With a total of seven patents to his name, Herrmann's work has the potential to impact the lives of many patients.

Latest Patents

Among his latest patents is a RANKL-specific agent for treating metastatic disease. This invention provides a RANKL-specific antagonistic agent that recognizes the human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL). It is designed for use in treating cancer patients to prevent or reduce premetastatic lesions in the blood. Another significant patent involves a method of treating nonalcoholic steatohepatitis by administering an antagonist human tumor necrosis factor receptor 1 (HUTNFR1) antibody. This antibody specifically recognizes human tumor necrosis factor 1 (hu TNFR1) and is intended for use in treating nonalcoholic steatohepatitis (NASH) and related disease conditions.

Career Highlights

Throughout his career, Herrmann has worked with several prominent companies, including Baliopharm AG and Probiocon GmbH. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Andreas Herrmann has collaborated with notable colleagues such as Klaus Pfizenmaier and Ludger Grosse-Hovest. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of medical research.

Conclusion

Andreas Herrmann's contributions to medical innovation through his patents and collaborations highlight his commitment to improving patient care. His work continues to pave the way for new treatments and advancements in the medical field.

Profile summary based on public USPTO records.